These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

92 related articles for article (PubMed ID: 18680450)

  • 1. Solubility improvement of an anthrax toxin peptide inhibitor by rational amino acid randomization.
    Pini A; Brunetti J; Falciani C; Fabbrini M; Bracci L
    Protein Pept Lett; 2008; 15(6):562-6. PubMed ID: 18680450
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Functional characterization of peptide-based anthrax toxin inhibitors.
    Gujraty K; Sadacharan S; Frost M; Poon V; Kane RS; Mogridge J
    Mol Pharm; 2005; 2(5):367-72. PubMed ID: 16196489
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Stable peptide inhibitors prevent binding of lethal and oedema factors to protective antigen and neutralize anthrax toxin in vivo.
    Pini A; Runci Y; Falciani C; Lelli B; Brunetti J; Pileri S; Fabbrini M; Lozzi L; Ricci C; Bernini A; Tonello F; Dal Molin F; Neri P; Niccolai N; Bracci L
    Biochem J; 2006 Apr; 395(1):157-63. PubMed ID: 16398644
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development of a receptor-based inhibitory penta-unit-conjugated peptide to enhance anthrax toxin neutralization.
    Lee SC; Yoon MY
    Int J Biol Macromol; 2020 Nov; 163():327-335. PubMed ID: 32619663
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Use of phage display and polyvalency to design inhibitors of protein-protein interactions.
    Mourez M; Collier RJ
    Methods Mol Biol; 2004; 261():213-28. PubMed ID: 15064461
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Polyvalent inhibitors of anthrax toxin that target host receptors.
    Basha S; Rai P; Poon V; Saraph A; Gujraty K; Go MY; Sadacharan S; Frost M; Mogridge J; Kane RS
    Proc Natl Acad Sci U S A; 2006 Sep; 103(36):13509-13. PubMed ID: 16938891
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Designing a polyvalent inhibitor of anthrax toxin.
    Mourez M; Kane RS; Mogridge J; Metallo S; Deschatelets P; Sellman BR; Whitesides GM; Collier RJ
    Nat Biotechnol; 2001 Oct; 19(10):958-61. PubMed ID: 11581662
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Peptide inhibitors MAP the way towards fighting anthrax pathogenesis.
    DeCathelineau AM; Bokoch GM
    Biochem J; 2006 Apr; 395(1):e1-3. PubMed ID: 16541485
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Peptide Probes Reveal a Hydrophobic Steric Ratchet in the Anthrax Toxin Protective Antigen Translocase.
    Colby JM; Krantz BA
    J Mol Biol; 2015 Nov; 427(22):3598-3606. PubMed ID: 26363343
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Improvement of an antibody neutralizing the anthrax toxin by simultaneous mutagenesis of its six hypervariable loops.
    Laffly E; Pelat T; Cédrone F; Blésa S; Bedouelle H; Thullier P
    J Mol Biol; 2008 May; 378(5):1094-103. PubMed ID: 18423488
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Structural biology: anthrax hijacks host receptor.
    Bann JG; Hultgren SJ
    Nature; 2004 Aug; 430(7002):843-4. PubMed ID: 15318206
    [No Abstract]   [Full Text] [Related]  

  • 12. The anthrax protective antigen (PA63) bound conformation of a peptide inhibitor of the binding of lethal factor to PA63: as determined by trNOESY NMR and molecular modeling.
    Hicks RP; Bhattacharjee AK; Koser BW; Traficante DD
    J Med Chem; 2004 Oct; 47(22):5347-55. PubMed ID: 15481973
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Probing the S2' Subsite of the Anthrax Toxin Lethal Factor Using Novel N-Alkylated Hydroxamates.
    Kurbanov EK; Chiu TL; Solberg J; Francis S; Maize KM; Fernandez J; Johnson RL; Hawkinson JE; Walters MA; Finzel BC; Amin EA
    J Med Chem; 2015 Nov; 58(21):8723-33. PubMed ID: 26492514
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification of a lead small-molecule inhibitor of anthrax lethal toxin by using fluorescence-based high-throughput screening.
    Wei D; Bu Z; Yu A; Li F
    BMB Rep; 2011 Dec; 44(12):811-5. PubMed ID: 22189685
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Three steps to targeting anthrax toxin.
    Lindsay J
    Trends Mol Med; 2002 Jan; 8(1):6. PubMed ID: 11796256
    [No Abstract]   [Full Text] [Related]  

  • 16. LRP6 holds the key to the entry of anthrax toxin.
    Bann JG; Cegelski L; Hultgren SJ
    Cell; 2006 Mar; 124(6):1119-21. PubMed ID: 16564002
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ligand-induced expansion of the S1' site in the anthrax toxin lethal factor.
    Maize KM; Kurbanov EK; Johnson RL; Amin EA; Finzel BC
    FEBS Lett; 2015 Dec; 589(24 Pt B):3836-41. PubMed ID: 26578066
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Structure-based design of a heptavalent anthrax toxin inhibitor.
    Joshi A; Kate S; Poon V; Mondal D; Boggara MB; Saraph A; Martin JT; McAlpine R; Day R; Garcia AE; Mogridge J; Kane RS
    Biomacromolecules; 2011 Mar; 12(3):791-6. PubMed ID: 21302959
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anthrax toxin lethal factor domain 3 is highly mobile and responsive to ligand binding.
    Maize KM; Kurbanov EK; De La Mora-Rey T; Geders TW; Hwang DJ; Walters MA; Johnson RL; Amin EA; Finzel BC
    Acta Crystallogr D Biol Crystallogr; 2014 Nov; 70(Pt 11):2813-22. PubMed ID: 25372673
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Interactions between anthrax toxin receptors and protective antigen.
    Scobie HM; Young JA
    Curr Opin Microbiol; 2005 Feb; 8(1):106-12. PubMed ID: 15694864
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.